[Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension].
The paper reviews current views of the problem of pulmonary hypertension. It shows the classification of pulmonary hypertension and considers the general issues of its pathogenesis, morphological changes, clinical picture, and main approaches to treating patients with pathology. Particular emphasis is placed on the review of clinical trials of the class of endothelin receptor antagonists.